1例泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症分析

doi:10.19803/j.1672-8629.2022.08.22

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (8): 921-923.
DOI: 10.19803/j.1672-8629.2022.08.22

1例泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症分析

钟运鸣¹, 李城², 邓映明², 熊天增¹, 孟小斌¹, 雷南凤¹, 梁培^3*

¹梅州市人民医院,广东梅州514000;
²梅州市食品药品监督检验所,广东梅州514000;
³南京大学医学院附属鼓楼医院,江苏南京210008

收稿日期:2020-12-04 出版日期:2022-08-15 发布日期:2022-08-15
通讯作者: ^*梁培,女,副主任药师,临床药学。E-mail：liangpeimail@163.com
作者简介:钟运鸣,男,硕士,主管药师,临床药学。

One case of peripheral eosinophilia induced by posaconazole oral suspension

ZHONG Yunming¹, Li Cheng², Deng Yingming², XIONG Tianzeng¹, MENG Xiaobin¹, Lei Nanfeng¹, LIANG Pei^2*

¹Meizhou People’s Hospital, Meizhou Guangdong 514000, China;
²Meizhou Institutes for Food and Drug Control, Meizhou Guangdong 514000, China;
³Nanjing Drum Tower Hospital, Nanjing Jiangsu 210008, China

Received:2020-12-04 Online:2022-08-15 Published:2022-08-15

摘要/Abstract

摘要： 目的探讨泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症的处置措施。方法结合文献检索,分析1例泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症的诊疗经过,探讨泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症的机制和应对措施。结果患者使用泊沙康唑口服混悬液23 d后出现外周嗜酸性粒细胞数增多,伴有头面部红肿、皮疹、瘙痒。立即给予口服氯雷他定片、静脉注射葡萄糖酸钙注射液及地塞米松磷酸钠注射液等对症治疗。对症治疗5 d后患者头面部红肿消退、皮疹、瘙痒逐渐消退,但外周嗜酸性粒细胞数仍逐渐增多,遂停用泊沙康唑口服混悬液。停用泊沙康唑口服混悬液10 d,复查外周嗜酸性粒细胞数逐渐减少。后因病情需要再次使用泊沙康唑口服混悬液,复查外周嗜酸性粒细胞数再次增多,遂在每次服用泊沙康唑混悬液前静脉注射地塞米松磷酸钠注射液,后复查患者外周嗜酸性粒细胞数逐渐恢复正常。结论泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症时应立即停药,或可在服药前静脉注射地塞米松磷酸钠注射液给予预防。

关键词: 泊沙康唑, 混悬液, 外周嗜酸性粒细胞增多症, 药品不良反应

Abstract: Objective To explore treatments against peripheral eosinophilia induced by posaconazole oral suspension. Methods The process of diagnosing and treating one case of peripheral eosinophilia induced by posaconazole oral suspension was analyzed. The mechanism by which posaconazole oral suspension induced peripheral eosinophilia was studied with reference to literature. Results The patient was diagnosed with peripheral eosinophilia 23 days after he took posaconazole oral suspension, accompanied by head and face swelling, rash and pruritus. The drug was suspended immediately. The patient’s condition gradually improved after the treatment with oral loratadine tablets, intravenous calcium gluconate injection and dexamethasone sodium phosphate injection. Head and face swelling subsided, skin rash was significantly mitigated, and itching disappeared within 10 days of withdrawal. Posaconazole suspension was taken a second time because of the patient’s condition. Dexamethasone sodium phosphate injection was injected intravenously before each oral posaconazole suspension before peripheral eosinophils gradually returned to normal. Conclusion The use of posaconazole suspension should be stopped immediately after the occurrence of peripheral eosinophilia, and dexamethasone can be injected intravenously before medication.

Key words: posaconazole, oral suspension, peripheral eosinophilia, adverse drug reaction

中图分类号:

R994.11
R978

钟运鸣, 李城, 邓映明, 熊天增, 孟小斌, 雷南凤, 梁培. 1例泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症分析[J]. 中国药物警戒, 2022, 19(8): 921-923.

ZHONG Yunming, Li Cheng, Deng Yingming, XIONG Tianzeng, MENG Xiaobin, Lei Nanfeng, LIANG Pei. One case of peripheral eosinophilia induced by posaconazole oral suspension[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 921-923.

参考文献

[1] TORRES HA, HACHEM RY, CHEMALY RF, et al.Posaconazole: a broad-spectrum triazole antifungal[J]. Lancet Infect Dis, 2005, 5(12): 775-785.
[2] TACKE D, KOEHLER P, MARKIEFKA B, et al.Our 2014 approachto mucormycosis[J]. Mycoses, 2014, 57(9): 519-524.
[3] CORNELY OA, ARIKAN-AKDAGLI S, DANNAOUI E, et al.ESCMID and ECMM joint clinical guide-lines for the diagnosis and management of mucormycosis 2013[J]. Clin Microbiol Infect, 2014, 20(3): 5-26.
[4] RILEY TT, MUZNY CA, SWIATLO E, et al.Breaking the mold: a review of mucormycosis and current pharmacological treatment options[J]. Ann Pharmacother, 2016, 50(9): 747-757.
[5] VAZQUEZ JA, SKIEST DJ, NIETO L, et al.A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS[J]. Clin Infect Dis, 2006, 42(8): 1179-1186.
[6] CORNELY OA, MAERTENS J, WINSTON DJ, et al.Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia[J]. N Engl J Med, 2007, 356(4): 348-359.
[7] ULLMANN AJ, LIPTON JH, VESOLE DH, et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. N Engl J Med, 2007, 356(4): 335-347.
[8] VISHNUBHOTLA P, IBRAHIM RB, ABIDI MH, et al.Fever and eosinophilia associated with voriconazole[J]. Ann Pharmacother, 2004, 38(5): 900-901.
[9] GRZEGORCZYK B, MURATA Y.Peripheral eosinophilia and eosinophilic colitis during long-term azole therapy for pulmonary aspergillosis[J]. JMM Case Rep, 2014, 1(4): e004135.
[10] MAHER A, RAE-KIRAN J, TERENCE W, et al.Marked peripheral eosinophilia due to prolonged administration of posaconazole[J]. JMM Case Rep, 2017, 4(6): e005100.
[11] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[12] NARANJO, CLAUDIO A, SHEAR, et al. Advances in the diagnosis of adverse drug reactions[J]. Journal of Clinical Pharmacology, 1992, 329(10): 897-904.
[13] LI X, CHU YQ.A case skin rash eosinophilia caused by tigecycline[J]. Clinical Medicaion Journal(临床药物治疗杂志), 2019, 17(11): 90-92.
[14] CUI HX, YU SW.Retrospective analysis of 125 cases of adverse drug reactions induced by tigecycline[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(8): 489-492.
[15] WALSH TJ, ANAISSIE EJ, DENNING DW, et al.Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
[16] FREIFELD AG, BOW EJ, SEPKOWITZ KA, et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2011, 52(4): 56-93.
[17] STEVENS DL, BISNO AL, CHAMBERS HF, et al.Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2014, 59(2): 10-52.
[18] PERFECT JR, DISMUKES WE, DROMER F, et al.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America[J]. Clin Infect Dis, 2010, 50(3): 291-322.

1例泊沙康唑口服混悬液致外周嗜酸性粒细胞增多症分析

One case of peripheral eosinophilia induced by posaconazole oral suspension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.